February 3, 2017 10:15 AM EST

Vowing to help, Trump manages to spark an angry protest against policies and a plan to revamp the FDA

Endpoints assesses the big biopharma stories of the week, with a little added commentary on what they mean for the industry.

President Donald J …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: Trump administration reveals 'most favored nation' drug price country targets

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Why Regeneron is buying 23andMe

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?